Protagonist Therapeutics, Inc.
PTGX
Rangering i aksjer
#2189
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Aksjekurs
$140.66
Markedsverdi
$9.10B
Endring (1 dag)
1.87%
Endring (1 år)
91.37%
Land
US
Handel Protagonist Therapeutics, Inc. (PTGX)
Kategori
Healthcare
Aksjeprishistorikk for Protagonist Therapeutics, Inc. (PTGX)
Høyeste sluttskurs: $138.70 den 2026-10-01
Laveste sluttskurs: $11.34 den 2016-08-01
Laveste sluttskurs: $11.34 den 2016-08-01
Aksjeprishistorikk for Protagonist Therapeutics, Inc. fra 2016 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | 21.89% |
| 2025 | 119.26% |
| 2024 | 92.93% |
| 2023 | 131.51% |
| 2022 | -72.05% |
| 2021 | 46.48% |
| 2020 | 203.82% |
| 2019 | 9.00% |
| 2018 | -65.01% |
| 2017 | -15.57% |
| 2016 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $536.91 | 25.90% |
US
|
|
| $230.20 | 757.36% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $892.44 | 9.61% |
NL
|
|
| $291.76 | 2.51% |
BE
|
